权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Nanomagnetic isolation and sensing for mobile HIV-1 self-testing

用于移动 HIV-1 自检的纳米磁隔离和传感

基本信息

批准号：
10002182
负责人：
David Aaron Issadore
金额：
$ 46.27万
依托单位：
UNIVERSITY OF PENNSYLVANIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-26 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10002182
关键词：
Acids Acquired Immunodeficiency Syndrome Advanced Development Antibodies Antigens Benchmarking Biological Markers Blood Blood Volume Car Phone Clinical Complex Coupled Data Analyses Detection Development Devices Diagnostic Disease Disease Progression Disease remission Drug resistance Early Diagnosis Elements Equipment Evaluation Fingers Future Geometry Goals Gold HIV HIV-1 Hand Home environment Human Label Laboratories Liquid substance Magnetism Methods Modeling Modification Monitor Nucleic Acids Oligonucleotides Outcome Patients Performance Plasma Preparation Procedures Reaction Recurrence Research Risk Sampling Specificity Specimen System T-Lymphocyte Technology Testing Time Variant Vesicle Viral Viral Load result Viremia Virus antiretroviral therapy base clinically relevant commercialization cost design drug efficacy graphene handheld mobile device individual patient innovation innovative technologies instrumentation manufacturability nanomagnetic nanopore nanoscale nanosensors noninvasive diagnosis novel nucleic acid detection point of care portability prototype sensor tissue culture transmission process treatment strategy viral detection viral rebound

项目摘要

Project Summary Antiretroviral treatment (ART) requires close monitoring of HIV-1 plasma viremia to confirm viral suppression, and to identify viral rebound due to nonadherence or drug resistance to initiate timely treatment modification. Thus, frequent efficient monitoring for HIV in blood via methods that are accessible for home self-testing is a critical need. Current self-detection strategies only detect antibody, and existing virus detection methods require extensive equipment and expertise (RNA) and/or have limited sensitivity (antigen). We aim to fill this gap with the development of an inexpensive, automated, portable system that will detect new or recurrent plasma viremia with high specificity and sufficient sensitivity for self-monitoring in these contexts. The ultimate goal of this project is to develop a platform technology for low-cost (< $2/test) point-of-care nucleic acid diagnostics for use on crude human samples (plasma) to quantitate viral RNA with a detection limit < 10 virus / sample (equivalent to a clinically-relevant threshold of 1000 copy/ml on 10 ul finger prick blood). The method will be simple to perform and will not require complex amplification procedures such as PCR. The novelty of our approach is to combine two innovative technologies invented by our team - one for target separation and concentration suitable for any starting blood volume, and one for label-free nucleic acid detection without amplification – into an integrated device. The goal of our R66 is to design a laboratory-based integrated system to demonstrate quantitation of HIV viral load on tissue culture derived virus spiked into healthy plasma. The goals of our R33 are advanced development of our technology into a fully-automated handheld mobile-phone based device to be used by non-microfluidic experts, and evaluation using banked clinical samples through partnership with Penn's Center for AIDS Research.

项目总结